Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study

SAT0145 Efficacy and Safety of Sirukumab in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of A Randomized, Double-Blind, Placebo-Controlled Study: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.3741 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 717.1-717

Author(s):

T. Takeuchi ◽

C. Thorne ◽

G. Karpouzas ◽

S. Sheng ◽

W. Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Drug Treatment ◽

Controlled Study ◽

Efficacy And Safety ◽

Treatment Results ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

The Journal of Rheumatology ◽

10.3899/jrheum.150613.c1 ◽

2016 ◽

Vol 43 (5) ◽

pp. 998-998

Keyword(s):

Rheumatoid Arthritis ◽

Japanese Patients ◽

Methotrexate Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind

Efficacy and Safety of Ketoprofen Patch in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Study

The Journal of Clinical Pharmacology ◽

10.1177/0091270009355813 ◽

2010 ◽

Vol 50 (10) ◽

pp. 1171-1179 ◽

Cited By ~ 4

Author(s):

Shinichi Kawai ◽

Eiji Uchida ◽

Masakazu Kondo ◽

Syuji Ohno ◽

Junichi Obata ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.34330 ◽

2012 ◽

Vol 64 (6) ◽

pp. 1730-1739 ◽

Cited By ~ 100

Author(s):

Michael Yellin ◽

Igor Paliienko ◽

Andra Balanescu ◽

Semen Ter-Vartanian ◽

Vira Tseluyko ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase Ii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Faculty Opinions recommendation of One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718241074.793528879 ◽

2017 ◽

Author(s):

Theresa Lu ◽

William Shipman ◽

Dragos Dasoveanu

Keyword(s):

Rheumatoid Arthritis ◽

Phase Ii ◽

Dose Finding ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

One Year

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.24266 ◽

2009 ◽

Vol 60 (2) ◽

pp. 335-344 ◽

Cited By ~ 159

Author(s):

Stanley B. Cohen ◽

Tien-Tsai Cheng ◽

Vishala Chindalore ◽

Nemanja Damjanov ◽

Ruben Burgos-Vargas ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Map Kinase ◽

Kinase Inhibitor ◽

P38 Map Kinase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

Annals of the Rheumatic Diseases ◽

10.1136/ard.2007.080002 ◽

2008 ◽

Vol 67 (8) ◽

pp. 1096-1103 ◽

Cited By ~ 335

Author(s):

M Schiff ◽

M Keiserman ◽

C Codding ◽

S Songcharoen ◽

A Berman ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Inadequate Response ◽

Efficacy And Safety ◽

Double Blind ◽

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy

SpringerPlus ◽

10.1186/s40064-015-0895-9 ◽

2015 ◽

Vol 4 (1) ◽

Cited By ~ 10

Author(s):

Kathryn Hobbs ◽

Atul Deodhar ◽

Brian Wang ◽

Bojena Bitman ◽

Joyce Nussbaum ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Dmard Therapy ◽

Faculty Opinions recommendation of Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1097731.553845 ◽

2008 ◽

Author(s):

Peter Taylor

Keyword(s):

Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Inadequate Response ◽

Efficacy And Safety ◽

Double Blind ◽